Qiagen N.v. · NYSE:QGEN
Qiagen — J.P. Morgan Healthcare Conference 2020
20 slides from Qiagen's conference presentation, Jan 13, 2020
Slide 1: Executing on differentiated Sample to Insight portfolio
Asha Palat and Brandon Mistretta, University of Houston, Texas Executing on differentiated Asha Palat, University of Houston, Texas Sample to Insight portfolio Thierry Bernard Interim CEO and Senior Vice President, Head of Molecular Diagnostics Business Area J.P. Morgan Healthcare Conference January
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate statements. All statements other than statements of historical fact are, or may be deemed to be (CER) basis,
Slide 3: Customers rely on QIAGEN to address key challenges in the century of biology
Customers rely on QIAGEN to address key challenges in the century of biology WE HELP 500,000 OUR COMMITMENT: CUSTOMERS TO ADVANCE MOLECULAR SCIENCE AND MEDICINE TO UNLOCK MOLECULAR INSIGHTS Academic Molecular >500 core products research diagnostics 5,100 employees Pharma Applied development testing
Slide 4: Dynamic and innovative portfolio to unlock valuable molecular insights
Dynamic and innovative portfolio to unlock valuable molecular insights Sample Technologies Assay Technologies Academia How can we achieve scientific breakthroughs even faster? • Sample collection and stabilization • PCR and NGS kits containing • DNA/RNA/protein purification kits reagents and consuma
Slide 5: QIAGEN leveraging its portfolio across the Life Sciences and Molecular Diagnostics continuum
QIAGEN leveraging its portfolio across the Life Sciences and Molecular Diagnostics continuum ~+6% annual market growth Academia Pharma Applied Testing Molecular Diagnostics Scientific breakthroughs Better and safer drugs Secure and protect Better healthcare QIAGEN addressable ~$3 billion ~$1 billion
Slide 6: Strong leadership positions create opportunities in scientific and clinical applications
Strong leadership positions create opportunities in scientific and clinical applications 2018 sales by customer class ~32% Academia / Applied Testing ~49% ~$1.5bn ~51% Molecular Life Diagnostics Sciences ~19% Pharma 2018 sales by product portfolio ~$1.5bn ~12% ~88% Instruments Consumables (incl. ser
Slide 7: Global presence with focus on the most attractive developed and emerging markets
Global presence with focus on the most attractive developed and emerging markets Sollentuna Distribution Aarhus partners Venlo Manchester Wroclaw in over 60 Toronto Hilden 2018 sales by geography Beverly Paris Milan Seoul countries Ankara Beijing Barcelona Tokyo Redwood City Cairo ~33% Germantown /
Slide 8: 2019: Delivering growth amid significant changes and developments
2019: Delivering growth amid significant changes and developments New orientation for clinical NGS strategy 2019 outlook • Started new partnership with Illumina (As of Oct 30, 2019) Q4 2019 outlook FY 2019 outlook • Discontinued internal NGS instrument development ~+3% CER ~+4% CER Net sales • Stopp
Slide 9: Executing platform launches: Setting the foundation for future growth
Executing platform launches: Setting the foundation for future growth 2018 2019 2020 2021 2022 2023 >$1 billion market QuantiFERON partnerships and menu expansion QFT Access QFT DiaSorin Hamilton and QFT DiaSorin EU Tecan handling U.S. >$800 million market QIAstat-Dx menu expansion QIAstat-Dx QIAsta
Slide 10: Sample Technologies: Expanding market leadership in new applications
Sample Technologies: Expanding market leadership in new applications Absolute leadership in sample preparation • >1 million samples processed daily in addressable market • >$700 million market opportunity with +2-3% CER annual growth • QIAGEN products cited in >200,000 publications to date • Solutio
Slide 11: QIAsymphony and QIAcube: Driving expansion of sample processing portfolio
QIAsymphony and QIAcube: Driving expansion of sample processing portfolio QIAsymphony QIAcube Connect NEW NEW >2,500 >660 new cumulative placements placements at in 2019 end-2019 Up to 192 samples per run Up to 14 samples per run • Intuitive modular system • New generation of automation for sample p
Slide 12: Digital PCR: Preparing launch of fully integrated nanoplate-based platform series
Digital PCR: Preparing launch of fully integrated nanoplate-based platform series Differentiated new solutions for digital PCR QIAGEN digital • Scalable instrument formats: 1-, 4- and 8-plate capabilities PCR technology • Quicker time to result and lower cost addressing On track for >$4.5 billion mi
Slide 13: QuantiFERON: Providing solutions to address global testing demands
QuantiFERON: Providing solutions to address global testing demands QuantiFERON-TB Gold Plus (QFT-Plus) QuantiFERON-TB Access (QFT-Access) Offering the 4th generation of the modern gold standard test Expanding TB test access to low resource, high-burden areas NEW No computer FDA approval No continuou
Slide 14: Infectious Diseases: Addressing urgent customer needs with next-generation systems
Infectious Diseases: Addressing urgent customer needs with next-generation systems NeuMoDx: Core / Hospital laboratory testing QIAstat-Dx: Syndromic testing • Rapid access to results in <1 hour • No reagent reconstitution needed – less that 1 min setup time • Broad menu with true random access • Res
Slide 15: NGS: Creating a differentiated portfolio targeting research and clinical lab opportunities
NGS: Creating a differentiated portfolio targeting research and clinical lab opportunities QIAGEN NGS portfolio components Universal NGS Solutions (For any sequencing platform) QIAGEN Digital Insights (Bioinformatics) Advancing NGS solutions for clinical MiSeq™Dx Illumina partnership decision making
Slide 16: QIAGEN Digital Insights: Introducing new portfolios from Discovery to Clinical Insights
QIAGEN Digital Insights: Introducing new portfolios from Discovery to Clinical Insights Discover new connections in data to support better outcomes • >1 million patients analyzed to date with QIAGEN Clinical Insight QIAGEN Digital Insights • >20 million curated findings covering scientific knowledge
Slide 17: Digitization: Targeted programs to support sales growth and increase profitability
Digitization: Targeted programs to support sales growth and increase profitability ~43% of 2019 sales via digital channels Creating one digital ecosystem QIAGEN.com ~65% of 2019 transactions Website relaunch via digital channels My QIAGEN >55,000 registered users QIAsphere New instrument connectivit
Slide 18: Improving profitability trends: Creating value during QIAGEN transformation
Improving profitability trends: Creating value during QIAGEN transformation Adjusted operating 24% ~27% income margin Adjusted diluted >$1.43-1.44 CER EPS trends $1.34 $1.27 (2016-2018 reported results) $1.11 2016 2017 2018 2019 outlook Sample to Insight J.P. Morgan Healthcare Conference 2020 18
Slide 19: Commitment to financial discipline: Supporting business growth while increasing returns
Commitment to financial discipline: Supporting business growth while increasing returns Business reinvestment Sustainable and profitable growth from Leverage ratio(1) current Sample to Insight portfolio 3.0 Disciplined Share repurchase programs capital 2.0 1.7 allocation Plan to return >$400 million
Slide 20: Looking ahead to 2020: Delivering growth with focus on value creation
Looking ahead to 2020: Delivering growth with focus on value creation Supporting customers across the continuum of Life Sciences to Molecular Diagnostics Executing on growth opportunities in a large and attractive molecular testing market Dynamic and innovative technologies reinforcing QIAGEN’s stro